Skip to main content
Hospital for Special Surgery Logo
phone 1.212.606.1000
Make an Appointment
1.212.606.1000 Make an Appointment

Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: The HSS Shoulder Arthroplasty Cohort

IRB Number: 26117

inactive

October 05, 2007

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Co-Investigators

Summary

We will enroll all TSA patients who undergo surgery at HSS and consent to be in the study.  We estimate this to be approximately 200 patients a year.  Patients will receive follow-up questionnaires at one year, two years and five years after their surgery.

Inclusion/Exclusion Criteria

Patients 18 years or older undergoing total shoulder arthroplasty at HSS

Contact Information

Principal Investigator
Lawrence Gulotta, MD
646.797.8735

Research Coordinator
Gregory Mahony
212.774.2449